Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers

References

• Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov. 2007;6(2):115–120.
   PubMed Web of Science ®Google Scholar
• Rosini M. Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem. 2014;6(5):485–487.
   PubMed Web of Science ®Google Scholar
• Nussinov R, Jang H, Tsai C-J. The structural basis for cancer treatment decisions. Oncotarget. 2014;5(17):7285–7302.
   PubMedGoogle Scholar
• Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043.
   PubMedGoogle Scholar
• Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery: miniperspective. J Med Chem. 2014;57(19):7874–7887.
   PubMed Web of Science ®Google Scholar
• Al-Karmalawy AA, Nafie MS, Shaldam MA, Elmaaty AA, Antar SA, El-Hamaky AA, Saleh MA, Elkamhawy A, Tawfik HO. Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J Med Chem. 2023;66(1):777–792.
   PubMed Web of Science ®Google Scholar
• Djulbegovic B, Kumar A, Soares HP, Hozo I, Bepler G, Clarke M, Bennett CL. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute – Sponsored Cooperative Oncology Groups, 1955 to 2006. Arch Intern Med. 2008;168(6):632–642.
   PubMedGoogle Scholar
• Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005;48(21):6523–6543.
   PubMed Web of Science ®Google Scholar
• Ragab MA, Eldehna WM, Nocentini A, Bonardi A, Okda HE, Elgendy B, Ibrahim TS, Abd-Alhaseeb MM, Gratteri P, Supuran CT, et al. 4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: design, synthesis, and biological assessments. Eur J Med Chem. 2023;250:115180.
   PubMed Web of Science ®Google Scholar
• Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.
   PubMed Web of Science ®Google Scholar
• El-Helby A-GA, Sakr H, Ayyad RR, Mahdy HA, Khalifa MM, Belal A, Rashed M, El-Sharkawy A, Metwaly AM, Elhendawy MA, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. Bioorg Chem. 2020;103:104233.
   PubMed Web of Science ®Google Scholar
• Farouk F, Elmaaty AA, Elkamhawy A, Tawfik HO, Alnajjar R, Abourehab MAS, Saleh MA, Eldehna WM, Al‐Karmalawy AA. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies. J Enzyme Inhib Med Chem. 2023;38(1):2171029.
   PubMed Web of Science ®Google Scholar
• Forterre P, Gribaldo S, Gadelle D, Serre M-C. Origin and evolution of DNA topoisomerases. Biochimie. 2007;89(4):427–446.
   PubMed Web of Science ®Google Scholar
• Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies. J Enzyme Inhib Med Chem. 2022;37(1):299–314.
   PubMed Web of Science ®Google Scholar
• Vann KR, Sedgeman CA, Gopas J, Golan-Goldhirsh A, Osheroff N. Effects of olive metabolites on DNA cleavage mediated by human type II topoisomerases. Biochemistry. 2015;54(29):4531–4541.
   PubMed Web of Science ®Google Scholar
• Xu X, Wu Y, Liu W, Sheng C, Yao J, Dong G, Fang K, Li J, Yu Z, Min X, et al. Discovery of 7‐methyl‐10‐hydroxyhomocamptothecins with 1, 2, 3‐triazole moiety as potent topoisomerase I inhibitors. Chem Biol Drug Des. 2016;88(3):398–403.
   PubMed Web of Science ®Google Scholar
• Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, Fornaciari G, Marini AM. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem. 2010;17(35):4270–4290.
   PubMed Web of Science ®Google Scholar
• Van Gijn R, Lendfers R, Schellens J, Bult A, Beijnen J. Dual topoisomerase I/II inhibitors. J Oncol Pharm Pract. 2000;6(3):92–108.
   Google Scholar
• Denny WA, Baguley BC. Dual topoisomerase I/II inhibitors in cancer therapy. Curr Top Med Chem. 2003;3(3):339–353.
   PubMed Web of Science ®Google Scholar
• Mišković K, Bujak M, Baus Lončar M, Glavaš-Obrovac L. Antineoplastic DNA-binding compounds: intercalating and minor groove binding drugs. Arh Hig Rada Toksikol. 2013;64(4):593–602.
   PubMed Web of Science ®Google Scholar
• Riou J-F, Fossé P, Nguyen CH, Larsen AK, Bissery M-C, Grondard L, Saucier J-M, Bisagni E, Lavelle F. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 1993;53(24):5987–5993.
   PubMed Web of Science ®Google Scholar
• Finlay G, Riou J-F, Baguley B. From amsacrine to DACA (N-[2-(dimethylamino) ethyl] acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer. 1996;32A(4):708–714.
   PubMed Web of Science ®Google Scholar
• Poddevin B, Riou J-F, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol . 1993;44(4):767–774.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998;4(3):683–691.
   PubMed Web of Science ®Google Scholar
• Utsugi T, Aoyagi K, Asao T, Okazaki S, Aoyagi Y, Sano M, Wierzba K, Yamada Y. Antitumor activity of a novel quinoline derivative, TAS‐103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res. 1997;88(10):992–1002.
   PubMedGoogle Scholar
• Yao B-L, Mai Y-W, Chen S-B, Xie H-T, Yao P-F, Ou T-M, Tan J-H, Wang H-G, Li D, Huang S-L, et al. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo [a] phenazin derivatives as dual topoisomerase I/II inhibitors. Eur J Med Chem. 2015;92:540–553.
   PubMed Web of Science ®Google Scholar
• Gjorgjieva M, Tomašič T, Barančokova M, Katsamakas S, Ilaš J, Tammela P, Peterlin Mašič L, Kikelj D. Discovery of benzothiazole scaffold-based DNA gyrase B inhibitors. J Med Chem. 2016;59(19):8941–8954.
   PubMed Web of Science ®Google Scholar
• Patravale AA, Gore AH, Kolekar GB, Deshmukh MB, Choudhari PB, Bhatia MS, Prabhu S, Jamdhade MD, Patole MS, Anbhule PV. Synthesis, biological evaluation and molecular docking studies of some novel indenospiro derivatives as anticancer agents. J Taiwan Inst Chem Eng. 2016;68:105–118.
   Web of Science ®Google Scholar
• Haider K, Shafeeque M, Yahya S, Yar MS. A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents. Eur J Med Chem Rep. 2022;5:100042.
   Google Scholar
• Korrapati SB, Yedla P, Pillai GG, Mohammad F, Ch VRR, Bhamidipati P, Amanchy R, Syed R, Kamal A. In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors. Biomed Pharmacother. 2021;134:111132.
   PubMed Web of Science ®Google Scholar
• Wu G, Ouyang L, Liu J, Zeng S, Huang W, Han B, Wu F, He G, Xiang M. Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via a regioselective three-component [3 + 2] cycloaddition and their preliminary antimicrobial evaluation. Mol Divers. 2013;17(2):271–283.
   PubMed Web of Science ®Google Scholar
• Chiacchio MA, Iannazzo D, Romeo R, Giofrè SV, Legnani L. Pyridine and pyrimidine derivatives as privileged scaffolds in biologically active agents. Curr Med Chem. 2019;26(40):7166–7195.
   PubMed Web of Science ®Google Scholar
• Özkay Y, Işıkdağ İ, İncesu Z, Akalın G. Synthesis of 2-substituted-N-[4-(1-methyl-4, 5-diphenyl-1H-imidazole-2-yl) phenyl] acetamide derivatives and evaluation of their anticancer activity. Eur J Med Chem. 2010;45(8):3320–3328.
   PubMed Web of Science ®Google Scholar
• El-Metwally SA, Khalil AK, El-Sayed WM. Design, molecular modeling and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as inhibitors of topoisomerase II. Bioorg Chem. 2020;94:103492.
   PubMed Web of Science ®Google Scholar
• Sekhar T, Thriveni P, Venkateswarlu A, Daveedu T, Peddanna K, Sainath SB. One-pot synthesis of thiazolo [3, 2-a] pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies. Spectrochim Acta A Mol Biomol Spectrosc. 2020;231:118056.
   PubMed Web of Science ®Google Scholar
• Nemr MT, AboulMagd AM. New fused pyrimidine derivatives with anticancer activity: synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study. Bioorg Chem. 2020;103:104134.
   PubMed Web of Science ®Google Scholar
• Baviskar AT, Banerjee UC, Gupta M, Singh R, Kumar S, Gupta MK, Kumar S, Raut SK, Khullar M, Singh S, et al. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity. Bioorg Med Chem. 2013;21(18):5782–5793.
   PubMed Web of Science ®Google Scholar
• Zhao M, Yang K, Zhu X, Gao T, Yu W, Liu H, You Z, Liu Z, Qiao X, Song Y. Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido [5, 4-b] indole and pyrazolo [3, 4-d] pyrimidine motifs. Eur J Med Chem. 2023;252:115303.
   PubMed Web of Science ®Google Scholar
• Farag B, Agili F, El‐Kalyoubi S, Said SA, Youssif S, Shehta W. Synthesis, molecular docking and anticancer activity of some 5‐aryl‐5, 10‐dihydropyrido [2, 3‐d: 6, 5‐d′] dipyrimidine‐2, 4, 6, 8‐tetraone derivatives and pyrido [2, 3‐d] pyrimidines. ChemistrySelect. 2022;7(7):e202103834.
   Web of Science ®Google Scholar
• Skalickova S, Milosavljevic V, Cihalova K, Horky P, Richtera L, Adam V. Selenium nanoparticles as a nutritional supplement. Nutrition. 2017;33:83–90.
   PubMed Web of Science ®Google Scholar
• Chhabria S, Desai K. Selenium nanoparticles and their applications. In: Encyclopedia of nanoscience and nanotechnology. Vol. 20; 2016. p. 1–32. https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Selenium+nanoparticles+and+their+applications.+In%3A+Encyclopedia+of+nanoscience+and+nanotechnology.&btnG=.
   Google Scholar
• Chaudhary S, Umar A, Mehta S. Surface functionalized selenium nanoparticles for biomedical applications. J Biomed Nanotechnol. 2014;10(10):3004–3042.
   PubMed Web of Science ®Google Scholar
• Ferro C, Florindo HF, Santos HA. Selenium nanoparticles for biomedical applications: from development and characterization to therapeutics. Adv Healthc Mater. 2021;10(16):e2100598.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F, Adel I, Tantawy MA. Novel uracil derivatives depicted potential anticancer agents: in vitro, molecular docking, and ADME study. Arab J Chem. 2022;15(4):103669.
   Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F. Synthesis, in silico prediction and in vitro evaluation of antitumor activities of novel pyrido [2, 3-d] pyrimidine, xanthine and lumazine derivatives. Molecules. 2020;25(21):5205.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi SA, Taher ES, Ibrahim TS, El-Behairy MF, Al-Mahmoudy AM. Uracil as a Zn-binding bioisostere of the allergic benzenesulfonamide in the design of quinoline–uracil hybrids as anticancer carbonic anhydrase inhibitors. Pharmaceuticals. 2022;15(5):494.
   Web of Science ®Google Scholar
• Dong LN, Wang YM, Zhang WL, Mo LP, Zhang ZH. Nickel supported on magnetic biochar as a highly efficient and recyclable heterogeneous catalyst for the one‐pot synthesis of spirooxindole‐dihydropyridines. Appl Organomet Chem. 2022;36(5):e6667.
   Web of Science ®Google Scholar
• Kavyani S, Baharfar R. Design and characterization of Fe3O4/GO/Au–Ag nanocomposite as an efficient catalyst for the green synthesis of spirooxindole‐dihydropyridines. Appl Organomet Chem. 2020;34(4):e5560.
   Web of Science ®Google Scholar
• El-Adl K, El-Helby A-GA, Ayyad RR, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, et al. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors. Bioorg Med Chem. 2021;29:115872.
   PubMed Web of Science ®Google Scholar
• Eissa IH, El-Helby A-GA, Mahdy HA, Khalifa MM, Elnagar HA, Mehany ABM, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, et al. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: design, synthesis, and anti-proliferative evaluation. Bioorg Chem. 2020;105:104380.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271–277.
   PubMed Web of Science ®Google Scholar
• Thabrew MI, Hughes RD, McFarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol. 1997;49(11):1132–1135.
   PubMed Web of Science ®Google Scholar
• El-Garawani IM, Hassab El-Nabi S. Increased sensitivity of apoptosis detection using direct DNA staining method and integration of acridine orange as an alternative safer fluorescent dye in agarose gel electrophoresis and micronucleus test. Can J Pure Appl Sci. 2016;102(2):3865–3871.
   Google Scholar
• Kardile RA, Sarkate AP, Borude AS, Mane RS, Lokwani DK, Tiwari SV, Azad R, Burra PV, Thopate SR. Design and synthesis of novel conformationally constrained 7, 12-dihydrodibenzo [b, h][1, 6] naphthyridine and 7H-chromeno [3, 2-c] quinoline derivatives as topoisomerase I inhibitors: in vitro screening, molecular docking and ADME predictions. Bioorg Chem. 2021;115:105174.
   PubMed Web of Science ®Google Scholar
• Patra N, De U, Kang J-A, Kim JM, Ahn MY, Lee J, Jung JH, Chung HY, Moon HR, Kim HS. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Eur J Pharmacol. 2011;658(2–3):98–107.
   PubMed Web of Science ®Google Scholar
• Atwal M, Swan RL, Rowe C, Lee KC, Lee DC, Armstrong L, Cowell IG, Austin CA. Intercalating TOP2 poisons attenuate topoisomerase action at higher concentrations. Mol Pharmacol. 2019;96(4):475–484.
   PubMed Web of Science ®Google Scholar
• Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci. 2000;113(Pt 5):753–757.
   PubMed Web of Science ®Google Scholar
• Belal A, Elanany MA, Santali EY, Al-Karmalawy AA, Aboelez MO, Amin AH, Abdellattif MH, Mehany ABM, Elkady H. Screening a panel of topical ophthalmic medications against MMP-2 and MMP-9 to investigate their potential in keratoconus management. Molecules. 2022;27(11):3584.
   PubMed Web of Science ®Google Scholar
• Sabt A, Abdelhafez OM, El-Haggar RS, Madkour HM, Eldehna WM, El-Khrisy EE-DA, Abdel-Rahman MA, Rashed LA. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies. J Enzyme Inhib Med Chem. 2018;33(1):1095–1107.
   PubMed Web of Science ®Google Scholar
• Maestro-Desmond interoperability tools. New York (NY): Schrödinger; 2017.
   Google Scholar
• Ma C, Taghour MS, Belal A, Mehany AB, Mostafa N, Nabeeh A, Eissa IH, Al-Karmalawy AA. Design and synthesis of new quinoxaline derivatives as potential histone deacetylase inhibitors targeting hepatocellular carcinoma: in silico, in vitro, and SAR studies. Front Chem. 2021;9:725135.
   PubMed Web of Science ®Google Scholar
• Khayat MT, Ahmed HEA, Omar AM, Muhammad YA, Mohammad KA, Malebari AM, Khayyat AN, Halawa AH, Abulkhair HS, Al-Karmalawy AA, et al. A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses. J Biomol Struct Dyn. 2023;1–19.
   Google Scholar
• Yuan S, Chan HS, Hu Z. Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci. 2017;7(2):e1298.
   Web of Science ®Google Scholar
• Raslan MA, Taher RF, Al-Karmalawy AA, El-Ebeedy D, Metwaly AG, Elkateeb NM, Ghanem A, Elghaish RA, Abd El Maksoud AI. Cordyline fruticosa (L.) A. Chev. leaves: isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. New J Chem. 2021;45(47):22216–22233.
   Web of Science ®Google Scholar
• El-Kalyoubi S, El-Sebaey SA, Rashad A, Al-Ghulikah HA, Ghorab MM, Elfeky SM. Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual topoisomerase II and HSP90 inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2198163.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F, Zordok WA, El-Sayed AS. Synthesis, in silico prediction and in vitro evaluation of antimicrobial activity, DFT calculation and theoretical investigation of novel xanthines and uracil containing imidazolone derivatives. Int J Mol Sci. 2021;22(20):10979.
   PubMed Web of Science ®Google Scholar
• Dabiri M, Azimi SC, Khavasi HR, Bazgir A. A novel reaction of 6-amino-uracils and isatins. Tetrahedron. 2008;64(30–31):7307–7311.
   Web of Science ®Google Scholar
• Emami S, Valipour M, Kazemi Komishani F, Sadati-Ashrafi F, Rasoulian M, Ghasemian M, Tajbakhsh M, Honarchian Masihi P, Shakiba A, Irannejad H, et al. Synthesis, in silico, in vitro and in vivo evaluations of isatin aroylhydrazones as highly potent anticonvulsant agents. Bioorg Chem. 2021;112:104943.
   PubMed Web of Science ®Google Scholar
• Varun,  Sonam,  Kakkar R. Isatin and its derivatives: a survey of recent syntheses, reactions, and applications. MedChemComm. 2019;10(3):351–368.
   PubMed Web of Science ®Google Scholar
• Kumar S, Nair AS, Abdelgawad MA, Mathew B. Exploration of the detailed structure–activity relationships of isatin and their isomers as monoamine oxidase inhibitors. ACS Omega. 2022;7(19):16244–16259.
   PubMed Web of Science ®Google Scholar
• Kapur M, Soni K, Kohli K. Green synthesis of selenium nanoparticles from broccoli, characterization, application and toxicity. Adv Tech Biol Med. 2017;5(1):2379.
   Google Scholar
• Ranjitha V, Ravishankar V. Extracellular synthesis of selenium nanoparticles from an actinomycetes Streptomyces griseoruber and evaluation of its cytotoxicity on HT-29 cell line. Pharm Nanotechnol. 2018;6(1):61–68.
   PubMedGoogle Scholar
• Khalil AM, Hassan ML, Ward AA. Novel nanofibrillated cellulose/polyvinylpyrrolidone/silver nanoparticles films with electrical conductivity properties. Carbohydr Polym. 2017;157:503–511.
   PubMed Web of Science ®Google Scholar
• Mourad MAE, Abo Elmaaty A, Zaki I, Mourad AAE, Hofni A, Khodir AE, Aboubakr EM, Elkamhawy A, Roh EJ, Al-Karmalawy AA. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2′,3′:4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity. J Enzyme Inhib Med Chem. 2023;38(1):2205043.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184(1):39–51.
   PubMed Web of Science ®Google Scholar
• Al-Muntaser SM, Al-Karmalawy AA, El-Naggar AM, Ali AK, Abd El-Sattar NEA, Abbass EM. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies. RSC Adv. 2023;13(18):12184–12203.
   PubMed Web of Science ®Google Scholar
• Hamed AA, El-Shiekh RA, Mohamed OG, Aboutabl EA, Fathy FI, Fawzy GA, Al-Taweel AM, Elsayed TR, Tripathi A, Al-Karmalawy AA. Cholinesterase inhibitors from an endophytic fungus Aspergillus niveus Fv-er401: metabolomics, isolation and molecular docking. Molecules. 2023;28(6):2559.
   PubMed Web of Science ®Google Scholar